ChinaBio® Executive Workshop
Developing a Successful Strategy for Entering the U.S. Market
Hosted by: Foley & Lardner LLP
Date: April 19, 2011 (Tuesday)
Location: The Westin Guangzhou
Time: 1:00 PM --- 17:30 PM
China’s “going-out” policy - Zou Chu Guo Men - encourages Chinese companies to expand abroad and actively engage in foreign investment. As more and more domestic biotech companies eye opportunities to invest in or expand to the U.S. life sciences market, it is critical for company executives and entrepreneurs to build a successful expansion plan that prepares your company for your next business move.
Foley is again proud to host the ChinaBio® Executive Workshop in Guangzhou on April 19, 2011. This half-day, complimentary seminar will explore critical aspects of developing an effective going-out strategy and a plan to protect and leverage your life science technology and intellectual capital in the U.S. market. Key topics include:
- Key 2010 developments in China’s life sciences industry and the current status of the “Zou Chu Guo Men” policy
- Commercializing China-originated technology in the U.S.
- Entering the U.S. market via strategic alliances, joint ventures, direct investment, and other strategic collaborations
- Investing in life science companies in the U.S.
- Maximizing returns on investments via the art and science of patent prosecution
Join other key executives and managers of biotechnology and life science companies interested in learning how to leverage their efforts in China to expand to the U.S. Learn “how to do it” from our speakers who are senior executives who have successfully put their principles into practice in the real world. Also meet other executives and managers from companies facing the same issues as you.
|1:00 -1:30 pm||Registration|
|1:45-2:10 pm||Key 2010 Developments in China’s Life Sciences Industry and The Current Status of The “Zou Chu Guo Men” Policy
- Greg B. Scott, President and Founder, ChinaBio® LLC
|2:10-2:50 pm||Practical Considerations Concerning Patent Litigation and Licensing in the United States
- Hon. Sharon R. Barner, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the USPTO (2009-2011) and Partner, Foley & Lardner LLP
|2:50-3:30 pm||Entering the US Market via Strategic Alliances, Joint Ventures, Direct Investment and Other Strategic Collaborations
- James C. Chapman, Partner, Foley & Lardner LLP
|3:30-3:45 pm||Networking Break|
|3:45-4:20 pm||HEC's Generic and New Drug Development Experience
- Gary Chen, Vice Director, R&D Institute, HEC Pharm Co., Ltd
|4:20-5:10 pm||The Art and Science of Building IPR Value Internationally
— Maximizing Investment in Patenting
- Stephen A. Bent, Partner, Foley & Lardner LLP
- James F. Ewing, Partner, Foley & Lardner LLP
|5:10-5:30 pm||Commercializing China-originated Technology in the U.S.
— What’s Important to the Overseas Partner?
- Stephen A. Bent, Partner, Foley & Lardner LLP
|5:30-6:30 pm||Networking Reception|
Hon. Sharon R. Barner - Partner, Foley & Lardner LLP
The Hon. Sharon R. Barner served as Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director, United States Patent and Trademark Office (2009-2011) before rejoining Foley & Lardner LLP as a partner. She served as a leader in intellectual property (IP) policy, helped develop and articulate the Obama Administration positions on all patent, trademark and copyright issues, both domestic and foreign, and helped promote strategies to thwart the theft of U.S. IP around the world. Ms. Barner is a leading attorney in the field of intellectual property law. She represents clients in a broad range of technologies and has tried numerous cases to verdict, as well as represents clients in IP strategic counseling and IP risk management.
Stephen A. Bent, JD - Partner, Foley & Lardner LLP
Stephen A. Bent, a partner with Foley & Lardner LLP, is a member of the Chemical, Biotechnology & Pharmaceutical Practice and the Health Care and Nanotechnology Industry Teams. He is the founder and a former co-chair of the Life Sciences Industry Team. Mr. Bent counsels clients on intellectual property disputes and the legal issues associated with pharmaceutical and biotechnology asset valuation and management, venture capital, licensing and technology transfer, and corporate acquisitions. He is a principal in the firm’s China initiative and is active in Foley & Lardner’s Shanghai office.
James C. Chapman, JD, MBA - Partner, Foley & Lardner LLP
James C. Chapman is a partner with Foley & Lardner LLP where he focuses on securities law, venture capital, mergers and acquisitions, and international business transactions. Mr. Chapman has more than 20 years experience in corporate and securities law and has been involved in over 200 mergers, acquisitions, and financing transactions. These transactions have included public offerings, private placements, debt financings, venture capital transactions, stock sales, asset sales, mergers, reorganizations, and recapitalizations. He is a member of the firm’s Private Equity & Venture Capital Practice and the Emerging Technologies Industry Team.
James F. Ewing, JD, PhD - Partner, Foley & Lardner LLP
James F. Ewing is vice chair of the Chemical, Biotechnology & Pharmaceutical Practice and a member of the Life Sciences, Food and Nanotechnology Industry Teams. Dr. Ewing primarily advises pharmaceutical, biotechnology, and nutraceutical clients. In the pharmaceutical and biotechnology sectors, Dr. Ewing works with companies engaged in drug discovery to develop and produce peptide and small molecule therapeutics, encompassing such technologies as computationally assisted drug design, immunology and vaccine technologies, stem cell technologies, neurobiology, drug delivery, gene therapy technologies, nanobiology technologies and biomedical devices.
Greg B. Scott - President and Founder, ChinaBio® LLC
Greg is an entrepreneur, angel investor and business advisor who has helped launch over thirty life science companies in the U.S. and China. He founded ChinaBio® LLC in January 2007 to identify and develop early stage life science companies in China and has helped raise over $400M in government and VC funding. ChinaBio also works with U.S. and European companies seeking partners, acquisitions and novel technologies in China. ChinaBio has organized ten investment conferences in China in just three years, and will hold its third annual ChinaBio® Partnering Forum in Beijing in May, 2011. This international event will draw over 600 attendees from around the globe. Greg is also the president and co-founder of Life Science Angels, an angel investment group that has funded 32 biotechnology and medical device companies in the U.S. and China since 2005, and Executive Editor of the ChinaBio® Today newsletter. Greg lives and works in Shanghai but visits the U.S. several times a year to enjoy California’s blue sky and sandy beaches.
Gary Chen - Vice Director, R&D Institute, HEC Pharm Co., Ltd.
Gary Chen was graduated from Hunan University for Chemistry and has years of R&D experiences. Gary Chen joined Hec Pharm Co., Ltd. in 2005 as R&D of generic drugs and used to be director of Synthetic Medicine dept. and Generic Drugs dept. Hec Pharm was authorized by Roche to produce anti-bird flu drug oseltamivir (Tamiflu) to support Chinese government in preventing and controlling flu in China. Hec Pharm was the third pharmaceutical to have this authority. That shows Hec Pharm Co., Ltd. has certain strength in API, preparation, R&D and management. Gary Chen played an very important role in this fact and lead Hec Pharm to great success on pharmaceutical R&D. Hec Pharm has applied two ANDA in US, and one of them would been approved this year. At the meanwhile, Hec Pharm is also doing great on the application of generic drugs in Europe.
This ChinaBio® Executive Workshop – Guangzhou will be held at:
The Westin Guangzhou (?????????) ?????
Orange Room (??), 5F
Address: No.6 Mid Linhe Road, Tianhe District, Guangzhou
Guangdong 510610, China Local Map
Tel: +86 20 2886 6868
- From the Guangzhou Baiyun International Airport, 40-60 min, 100-150RMB (one way)
or take the Line 6C airport shuttle bus to the Tianhe Houjilou stop
- From the Guangzhou East (or Tianhe) Railway Station, about 3 min, 9 RMB (one way)
- From the Guangzhou North (or Old) Railway Station, about 50min, 30-40 RMB (one way)
- From the Guangzhou South (or New) Railway Station, about 50min, 30-40 RMB (one way)
For driving directions, please contact the hotel.
We would like to thank Foley & Lardner for hosting this seminar:
- Foley & Lardner LLP – Foley is a highly regarded, international law firm providing client-focused, industry-specific services that result in high-value legal counsel for our clients. Our practice areas encompass the full range of corporate legal services. With an office located in Shanghai, the attorneys of Foley’s China Practice are well positioned to assist U.S., Asian, and European clients with the complex matters that arise when doing business in or related to Greater China. From IP procurement and technology transfer to M&A due diligence, count on Foley’s experience and our cultural and business connections in China to help you stake you claim. www.foley.com
We would also like to thank the following partners for making this event possible:
- Cyagen Biosciences - Cyagen was established to develop technologies in stem cell research, genetic engineering and transgenic animal research to serve the growing needs from life sciences labs and drug discovery companies. The principals of Cyagen consist of world-class scientists, senior industry experts and professional managers from both the U.S. and China. Cyagen's 1600 square meter main R&D and production facility is located in the Science City on the outskirt of Guangzhou, encompassing a laminar flow ultra-clean cell culture lab built to GMP standard, a molecular biology lab, and an animal barrier facility housing mice and rats intended for transgenic and gene knockout research. The business philosophy of Cyagen is to create a competitive advantage by marrying cutting-edge technologies in the U.S. with cost effectiveness R&D in China, and to use this advantage to bring top-quality reagents, tools and services to researchers around the world at favorable prices. www.cyagen.com
- Guangzhou Economic & Technological Development District (GETDD) – Guangzhou Economic & Technological Development District?GETDD?was established in December 1984 with the approval of the State Council and covers an area of over 60.6 km2. Since its establishment, GETDD has attracted many hi-tech and biotech companies to the area, building a modern industry base in the development district and creating an environment attractive to early stage life science companies as well as established companies. GETDD is considered to be one of the leading state development districts in China. eng.luogang.gov.cn
- Guangzhou Biotechnology Center - Guangzhou Biotechnology Center under the jurisdiction of the Biotechnology Steering Group and the Sciences &Technology Bureau of Guangzhou Municipal Government is a service agency specializing in biotechnology industry. Its key missions are to develop the biotechnology industry of Guangzhou and to accelerate the transfer of S&T achievements and parallel cooperation and exchange. www.gzbio.org
- Guangzhou OCS - Guangzhou Convention of Overseas Chinese Scholars in Science and Technology (OCS), annually held in December, Guangzhou, is the major platform for exchanges of technologies, investment, intellectual and information between overseas Chinese scholars and domestic institutions. Started from 1998, OCS has been officially hosted by the Ministry of Education, Ministry of Science and Technology, Ministry of Human Resource and Social Security, Chinese Academy of Sciences, Overseas Chinese Affairs Office of the State Council and Guangzhou Municipal Government, and gained support from 14 city governments and 3 national organizations. The 13th OCS has been held in Guangzhou Baiyun International Convention Center, Dec 20th -22nd, 2010. This session comes out to be a high-level, most influential, innovated and effective event with great success. 2036 overseas high-end professionals and over 2000 domestic organizations gather for this event to share minds in technology investment as well as talent introduction. The 14th OCS will be held in Guangzhou in December, 2011, and we always extend our warm welcome to investors. www.ocs-gz.gov.cn
- ChinaBio® Today – China has surpassed Japan the second largest pharmaceutical market in the world, and is growing at an astounding 22% per year. Now, after billions of dollars of government and private investment, China is transforming itself into a world leader in biotechnology. ChinaBio® Today is the most widely read source focusing exclusively on China’s rapidly evolving life science industry, with over 18,000 readers. From our offices in Shanghai and San Diego, we provide daily news, commentary and analysis on public and private China life science companies, as well as global issues affecting the China market. www.ChinaBioToday.com.
About ChinaBio® LLC
Since its founding in January, 2007, ChinaBio® LLC has rapidly launched a number of initiatives accelerating the globalization of China’s life science industry. ChinaBio has helped China companies raise nearly $400 million and global life science companies identify over 400 licensing and acquisition opportunities in China.
- Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 4,000 attendees.
- Consulting: ChinaBio works with global life science companies and China entrepreneurs to define and execute a successful global strategy.
- Transactions: ChinaBio Capital helps companies secure partnerships and acquisitions and access private and government funding in China.
- Publishing: ChinaBio® Today is the most widely read online and email newsletter on China’s life science industry.
More information is available at www.ChinaBioLLC.com.